ResMed Inc. (NYSE:RMD) Shares Acquired by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC boosted its holdings in ResMed Inc. (NYSE:RMD) by 4.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,397 shares of the medical equipment provider’s stock after buying an additional 198 shares during the period. Motley Fool Asset Management LLC’s holdings in ResMed were worth $756,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its holdings in shares of ResMed by 224.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 185 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 128 shares during the period. Planned Solutions Inc. purchased a new stake in shares of ResMed during the 4th quarter valued at about $34,000. MV Capital Management Inc. raised its holdings in shares of ResMed by 39.0% during the 4th quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock valued at $37,000 after buying an additional 60 shares during the period. Operose Advisors LLC purchased a new stake in shares of ResMed during the 3rd quarter valued at about $32,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in shares of ResMed during the 4th quarter valued at about $45,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 10,935 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the sale, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other ResMed news, General Counsel Michael J. Rider sold 200 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the transaction, the general counsel now owns 6,688 shares in the company, valued at $1,158,696. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of the business’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,216 shares of company stock valued at $2,046,617. Corporate insiders own 1.21% of the company’s stock.

Analyst Ratings Changes

RMD has been the subject of a number of recent analyst reports. Needham & Company LLC raised their price objective on ResMed from $224.00 to $236.00 and gave the company a “buy” rating in a research note on Friday. Mizuho restated a “buy” rating and set a $215.00 price objective on shares of ResMed in a research note on Wednesday, March 27th. UBS Group lifted their target price on ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Thursday, January 25th. JPMorgan Chase & Co. lifted their target price on ResMed from $160.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 9th. Finally, Oppenheimer decreased their target price on ResMed from $205.00 to $200.00 and set an “outperform” rating for the company in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, ResMed currently has an average rating of “Moderate Buy” and a consensus target price of $202.80.

ResMed Stock Performance

ResMed stock traded up $34.64 during mid-day trading on Friday, hitting $218.06. 4,330,318 shares of the company’s stock traded hands, compared to its average volume of 1,056,215. The firm has a 50 day moving average price of $187.07 and a 200 day moving average price of $171.97. The company has a quick ratio of 1.89, a current ratio of 3.11 and a debt-to-equity ratio of 0.27. The company has a market cap of $32.07 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 2.25 and a beta of 0.67. ResMed Inc. has a one year low of $132.24 and a one year high of $243.52.

ResMed (NYSE:RMD) last announced its earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.22. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $1.68 EPS. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities analysts forecast that ResMed Inc. will post 7.47 EPS for the current year.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.